What is Oncternal Therapeutics Inc Annual Net Profit?

Oncternal Therapeutics Inc Annual Net Profit rose 5.36% in the last year to $39.48 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

What is Oncternal Therapeutics Inc Price to Earning Ratio?

Oncternal Therapeutics Inc Price to Earning Ratio is -0.05, which is negative.

What is Oncternal Therapeutics Inc Stock Price?

Oncternal Therapeutics Inc Stock Price fell 93.8% and underperformed its sector by 102.95% in the past year.

What is Oncternal Therapeutics Inc Quarterly Net profit?

Oncternal Therapeutics Inc Quarterly Net profit rose 14.18% YoY to $8.46 M. Its sector's average net profit growth YoY for the quarter was -41.97%.

What is Oncternal Therapeutics Inc Debt to Equity Ratio?

Oncternal Therapeutics Inc Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Oncternal Therapeutics Inc Return on Equity(ROE)?

Oncternal Therapeutics Inc Return on Equity(ROE) for the last financial year was -86.75%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Oncternal Therapeutics Inc Mutual Fund Holding?

Oncternal Therapeutics Inc Mutual Fund Holding decreased by 0.12% in the last quarter to 6.22.

What is Oncternal Therapeutics Inc Promoter Share Holding?

Oncternal Therapeutics Inc Promoter Share Holding stayed the same in the most recent quarter at 41.79%.

What is Oncternal Therapeutics Inc Institutional Holding?

Oncternal Therapeutics Inc Institutional Holding remained the same in the last quarter at 0.01%.

How is the Oncternal Therapeutics Inc today?

The Oncternal Therapeutics Inc today is trading in the down by 0.00% at 0.53.

How has Oncternal Therapeutics Inc performed historically?

The Oncternal Therapeutics Inc is currently trading down 0.00% on an intraday basis in the past week the index fell 0.00%. The index has been down 0.00% in the past quarter and fell -93.80% in the past year. You can view this in the overview section.

Oncternal Therapeutics Inc XNAS: ONCT

Oncternal Therapeutics Inc Live Share Price Today, Share Analysis and Chart

Name: Oncternal Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Oncternal Therapeutics Inc
Rating: 0.73483325
Author: Trendlyne DVM scores

Download real time

0.53 0.00 (0.00%)

New 52W Low today

- XNAS Volume

XNAS 22 Apr, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Oncternal Therapeutics Inc is on 25 Apr 2025 for the purpose of Oncternal Therapeutics Inc Annual Report for 2024 See details

Oncternal Therapeutics Inc Key Metrics

My Metrics

Select

Market Capitalization Low in industry Unavailable in chosen country	1.6
Price to Book Low in industry Unavailable in chosen country	0.2
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	14.2
Net Profit TTM Growth % Below industry Median Unavailable in chosen country	17.1
Piotroski Score Low in industry Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	0.6
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-86.7
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-74.9

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

16.3 / 100

Technically Bearish

13.1 / 100

No estimates available

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Oncternal Therapeutics Inc Stock Price Analysis

52 Week Price Range

-93.8% 1 Year return

0.5 (LTP)

0.59.9

LowHigh

View full Share Price History

Oncternal Therapeutics Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Oncternal Therapeutics Inc Stock Analysis

Oncternal Therapeutics Inc stock analysis with key metrics, changes, and trends.

Oncternal Therapeutics Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$39.48 M	5.36%	positive	Annual Net Profit rose 5.36% in the last year to $39.48 M. Its sector's average net profit growth for the last fiscal year was -32.44%.
Price to Earning Ratio	-0.05	-	negative	Price to Earning Ratio is -0.05, which is negative.
Stock Price	$0.53	-93.8%	negative	Stock Price fell 93.8% and underperformed its sector by 102.95% in the past year.
Quarterly Net profit	$8.46 M	14.18%	positive	Quarterly Net profit rose 14.18% YoY to $8.46 M. Its sector's average net profit growth YoY for the quarter was -41.97%.
Debt to Equity Ratio	0.01	-	positive	Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-86.75 %	-86.75%	negative	Return on Equity(ROE) for the last financial year was -86.75%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	6.22 %	-0.12%	negative	Mutual Fund Holding decreased by 0.12% in the last quarter to 6.22.
Promoter Share Holding	41.79 %	0%	neutral	Promoter Share Holding stayed the same in the most recent quarter at 41.79%.
Institutional Holding	0.01 %	0%	neutral	Institutional Holding remained the same in the last quarter at 0.01%.

VIEW LESS

Loading data..

Oncternal Therapeutics Inc - Company Profile

What does Oncternal Therapeutics Inc do?

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.

Oncternal Therapeutics Inc Management structure

All Gross Remunerations are in USD

Dr. Salim Yazji, M.D.

Chief Medical Officer

2024

Gross Remuneration

Year

Dr. James B. Breitmeyer, M.D.,PhD

President, Chief Executive Officer and Director

2024

Gross Remuneration

Year

Mr. Richard G. Vincent

Chief Financial Officer and Treasurer

2024

Gross Remuneration

Year

Oncternal Therapeutics Inc Board of directors

All Gross Remunerations are in USD

Dr. Xin Nakanishi, PhD

Independent Director

2024

Gross Remuneration

Year

Dr. James B. Breitmeyer, M.D.,PhD

President, Chief Executive Officer and Director

2024

Gross Remuneration

Year

Oncternal Therapeutics Inc Live Share Price Today, Share Analysis and Chart

New 52W Low today

Oncternal Therapeutics Inc Key Metrics

Market Capitalization

Price to Book

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

Price to Book

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Oncternal Therapeutics Inc Stock Price Analysis

52 Week Price Range

Oncternal Therapeutics Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Oncternal Therapeutics Inc Stock Analysis

Oncternal Therapeutics Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit rose 5.36% in the last year to $39.48 M. Its sector's average net profit growth for the last fiscal year was -32.44%.

Price to Earning Ratio is -0.05, which is negative.

Stock Price fell 93.8% and underperformed its sector by 102.95% in the past year.

Quarterly Net profit rose 14.18% YoY to $8.46 M. Its sector's average net profit growth YoY for the quarter was -41.97%.

Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -86.75%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 0.12% in the last quarter to 6.22.

Promoter Share Holding stayed the same in the most recent quarter at 41.79%.

Institutional Holding remained the same in the last quarter at 0.01%.

Oncternal Therapeutics Inc - Company Profile

What does Oncternal Therapeutics Inc do?

Oncternal Therapeutics Inc Management structure

Dr. Salim Yazji, M.D.

Chief Medical Officer

Dr. James B. Breitmeyer, M.D.,PhD

President, Chief Executive Officer and Director

Mr. Richard G. Vincent

Chief Financial Officer and Treasurer

Oncternal Therapeutics Inc Board of directors

Dr. Xin Nakanishi, PhD

Independent Director

Dr. James B. Breitmeyer, M.D.,PhD

President, Chief Executive Officer and Director

Oncternal Therapeutics Inc FAQ

How is Oncternal Therapeutics Inc today?

Oncternal Therapeutics Inc today is trading in the red, and is down by 0.00% at 0.53.

How has Oncternal Therapeutics Inc performed historically?

Oncternal Therapeutics Inc is currently trading down 0.00% on an intraday basis. In the past week the stock fell 0.00%. stock has been down 0.00% in the past quarter and fell -93.80% in the past year. You can view this in the overview section.